Variability in bacteriophage and antibiotic sensitivity in serial Pseudomonas aeruginosa isolates from cystic fibrosis airway cultures over 12 months
File(s)
Published version
Author(s)
Martin, Isaac
Kenna, Dervla
Morales, Sandra
Alton, Eric WFW
Davies, Jane
Type
Journal Article
Abstract
Antibiotic treatment for Pseudomonas aeruginosa (Pa) in cystic fibrosis is limited in efficacy and may lead to multi-drug resistance (MDR). Alternatives such as bacteriophages are being explored but well designed, and controlled trials are crucial. The rational selection of patients with bacteriophage susceptible infections is required for both safety and efficacy monitoring. We questioned whether bacteriophage susceptibility profiles were constant or variable over time, variability having been reported with antibiotics. Serial Pa isolates (n = 102) from 24 chronically infected cystic fibrosis (CF) patients over one year were investigated with plaque and antibiotic disc diffusion assays. Variable number tandem repeat (VNTR) analysis identified those patients with >1 isolate. A median (range) of 4 (3–6) isolates/patient were studied. Twenty-one (87.5%) individuals had a single VNTR type; three (12.5%) had two VNTR types at different times. Seventy-five percent of isolates were sensitive to bacteriophage at ≥ 1 concentration; 50% of isolates were antibiotic multidrug resistant. Serial isolates, even when representing a single VNTR type, varied in sensitivity to both bacteriophages and antibiotics. The rates of sensitivity to bacteriophage supports the development of this therapy; however, the variability in response has implications for the selection of patients in future trials which must be on the basis of current, not past, isolate testing.
Date Issued
2021-03-22
Date Acceptance
2021-03-17
Citation
Mircoorganisms, 2021, 9 (3)
ISSN
2076-2607
Publisher
MDPI
Journal / Book Title
Mircoorganisms
Volume
9
Issue
3
Copyright Statement
© 2021 by the authors.Licensee MDPI, Basel, Switzerland.This article is an open access articledistributed under the terms andconditions of the Creative CommonsAttribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)
License URL
Sponsor
Cystic Fibrosis Trust
Grant Number
SRC 001
Subjects
Science & Technology
Life Sciences & Biomedicine
Microbiology
bacteriophage
Pseudomonas aeruginosa
antimicrobial resistance
cystic fibrosis
novel antimicrobials
adjunctive therapy
pulmonary infection
Pseudomonas aeruginosa
adjunctive therapy
antimicrobial resistance
bacteriophage
cystic fibrosis
novel antimicrobials
pulmonary infection
Publication Status
Published
Article Number
ARTN 660